BRISTOL MYERS SQUIBB CO
For the period ended Jun 30, 2024. Filed Jul 26, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Jul 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2024 Senior Unsecured Notes | Aggregate principal amount of $13.0 billion of unsecured senior notes issued by BMS in February 2024 | LBCL | Large B-cell Lymphoma |
|---|---|---|---|
| aGVHD | acute graft-versus-host disease | Mirati | Mirati Therapeutics, Inc. |
| ANDA | Abbreviated New Drug Application | MPM | malignant pleural mesothelioma |
| AstraZeneca | AstraZeneca PLC | MTA | Methylthioadenosine |
| BCMA | B-cell maturation antigen-directed | NKT | natural killer T cells |
| CAR-T | chimeric antigen receptor T-cell | NDA | New Drug Application |
| Celgene | Celgene Corporation | NSCLC | non-small cell lung cancer |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | NTRK | Neurotrophic Tropomyosin Receptor Kinase |
| CGDP | Coverage Gap Discount Program | Nimbus | Nimbus Therapeutics |
| CLL | Chronic Lymphocytic Leukemia | NVAF | non-valvular atrial fibrillation |
| CML | chronic myeloid leukemia | OECD | Organization for Economic Co-operation and Development |
| CRC | colorectal carcinoma | Ono | Ono Pharmaceutical Co., Ltd |
| CTLA4 | Cytotoxic T-lymphocyte Antigen-4 | Otsuka | Otsuka Pharmaceutical Co., Ltd. |
| DLBCL | Diffuse Large B-cell Lymphoma | PD-1 | programmed cell death protein 1 |
| EC | European Commission | PDUFA | Prescription Drug User Fee Act |
| Eisai | Eisai Co., Ltd. | PsA | psoriatic arthritis |
| EPS | earnings per share | PRMT5 | protein arginine methyltransferase 5 |
| EU | European Union | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 |
| Exchange Act | the Securities Exchange Act of 1934 | R&D | research and development |
| FASB | Financial Accounting Standards Board | RA | rheumatoid arthritis |
| FDA | U.S. Food and Drug Administration | RayzeBio | RayzeBio, Inc. |
| FL | follicular lymphoma | RCC | renal cell carcinoma |
| GAAP | generally accepted accounting principles | REMS | risk evaluation and mitigation strategy |
| GTN | gross-to-net | Sanofi | Sanofi S.A. |
| HCC | hepatocellular carcinoma | SEC | U.S. Securities and Exchange Commission |
| HCM | hypertrophic cardiomyopathy | SLL | Small Lymphocytic Lymphoma |
| IPRD | in-process research and development | SPC | Supplementary Protection Certificate |
| IRA | Inflation Reduction Act of 2022 | SystImmune | SystImmune, Inc. |
| IRS | Internal Revenue Service | Takeda | Takeda Pharmaceutical Company Limited |
| IV | intravenous | TCJA | Tax Cuts and Jobs Act |
| JIA | juvenile idiopathic arthritis | Turning Point | Turning Point Therapeutics, Inc. |
| Juno | Juno Therapeutics, Inc. | UC | ulcerative colitis |
| Karuna | Karuna Therapeutics, Inc. | UK | United Kingdom |
| KRAS | Kirsten rat sarcoma | U.S. | United States |
| MDL | multi-district litigation | USPTO | U.S. Patent and Trademark Office |
| MDS | myelodysplastic syndromes | VAT | value added tax |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.